UFPT vs VRDN: Which Stock Is the Better Buy?
UFP Technologies, Inc. and Viridian Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — UFPT vs VRDN, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| UFP Technologies, Inc. (UFPT) | Viridian Therapeutics, Inc. (VRDN) | |
|---|---|---|
| Market cap | $1.8B | $1.8B |
| Revenue (latest FY) | $602.80M | $70.85M |
| Net income (latest FY) | $68.31M | $-342.60M |
| Revenue growth (5y CAGR) | 27.4% | 132.2% |
| Net margin | 11.3% | -483.6% |
| Return on equity | 16.1% | -47.4% |
| P/E ratio | 26.5 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 10 | 0 |
| Positive free cash flow | — | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full UFPT vs VRDN breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open UFPT's full financials → Open VRDN's full financials →More comparisons
Frequently asked questions
Which is bigger, UFPT or VRDN?
UFP Technologies, Inc. is larger by market capitalization — $1.8B versus $1.8B.
Which grows faster, UFPT or VRDN?
Over the last five fiscal years, Viridian Therapeutics, Inc. grew revenue faster — 132.2%/yr versus 27.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.